nach oben

Erschienen in:

15.01.2022 | Review

Thyroid disorders and cardiovascular manifestations: an update

verfasst von: Stavroula A. Paschou, Evanthia Bletsa, Panagiota K. Stampouloglou, Vasiliki Tsigkou, Angeliki Valatsou, Katerina Stefanaki, Paraskevi Kazakou, Michael Spartalis, Eleftherios Spartalis, Evangelos Oikonomou, Gerasimos Siasos

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing a major health, social, and economic issue. Thyroid disorders are very common and affect >10% of the adult population in total. The aim of this review is to describe the physiologic role of thyroid hormones on cardiovascular system, to present cardiovascular manifestations in patients with thyroid disorders, emphasizing in molecular mechanisms and biochemical pathways, and to summarize current knowledge of treatment options. Thyroid hormone receptors are located both in myocardium and vessels, and changes in their concentrations affect cardiovascular function. Hyperthyroidism or hypothyroidism, both clinical and subclinical, without the indicated therapeutical management, may contribute to the progression of CVD. According to recent studies, even middle changes in thyroid hormones levels increase cardiovascular mortality from 20% to 80%. In more details, thyroid disorders seem to have serious effects on the cardiovascular system via plenty mechanisms, including dyslipidemia, hypertension, systolic and diastolic myocardial dysfunction, as well endothelial dysfunction. On top of clinical thyroid disorders management, current therapeutics focus on younger patients with subclinical hypothyroidism and elderly patients with subclinical hyperthyroidism.

G.R. Murray, Note on the treatment of myxoedema by hypodermic injections of an extract of the thyroid gland of a sheep. Br. Med. J. 2, 796–797 (1891)CrossRef

G.R. Murray, The life-history of the first case of myxoedema treated by thyroid extract. Br. Med. J. 13, 359–360 (1920)CrossRef

J.H. Moyer, A current appraisal of drug therapy of atherosclerosis. Arch. Environ. Health 14, 337–347 (1967). https://doi.org/10.1080/00039896.1967.10664743CrossRefPubMed

The Coronary Drug Project, Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA 220, 996–1008 (1972)CrossRef

N. Townsend, D. Kazakiewicz, F. Lucy Wright, A. Timmis, R. Huculeci, A. Torbica, C.P. Gale, S. Achenbach, F. Weidinger, P. Vardas, Epidemiology of CVD in Europe. Nat. Rev. Cardiol. 2021 Sep. https://doi.org/10.1038/s41569-021-00607-3

Atlas Writing Group; ESC Atlas of Cardiology is a compendium of cardiovascular statistics compiled by the European Heart Agency, a department of the European Society of Cardiology.; Developed in collaboration with the national societies of the European Society of Cardiology member countries, A. Timmis, N. Townsend, C.P. Gale, A. Torbica, M. Lettino, S.E. Petersen, E.A. Mossialos, A.P. Maggioni, D. Kazakiewicz, H.T. May, D. De Smedt, M. Flather, L. Zuhlke, J.F. Beltrame, R. Huculeci, L. Tavazzi, G. Hindricks, J. Bax, B. Casadei, S. Achenbach, L. Wright, P. Vardas, European Society of Cardiology: CVD Statistics 2019 (Executive Summary). Eur. Heart J. Qual. Care Clin. Outcomes 6, 7–9 (2020). https://doi.org/10.1093/ehjqcco/qcz065CrossRef

GBD, 2017 Disease and Injury Incidence and Prevalence Collaborators.: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018). https://doi.org/10.1016/S0140-6736(18)32279-7CrossRef

N.N. Jones, A.K. Roalfe, I. Adoki, F.D. Hobbs, C.J. Taylor, Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur. J. Heart Fail. 21, 1306–1325 (2019). https://doi.org/10.1002/ejhf.1594CrossRefPubMed

E. Wilkins, L. Wilson, K. Wickramasinghe, P. Bhatnagar, J. Leal, R. Luengo-Fernandez, R. Burns, M. Rayner, N. Townsend. European CVD Statistics 2017. (European Heart Network, Brussels), 2017)

10.

P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J.H. Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301–316 (2018). https://doi.org/10.1038/nrendo.2018.18CrossRefPubMed

11.

A. Garmendia Madariaga, S. Santos Palacios, F. Guillén-Grima, J.C. Galofré, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–31 (2014). https://doi.org/10.1210/jc.2013-2409CrossRefPubMed

12.

J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’Leary, P.J. Leedman, P. Feddema, V. Michelangeli, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch. Intern Med. 165, 2467–72 (2005). https://doi.org/10.1001/archinte.165.21.2467CrossRefPubMed

13.

N. Silva, O. Santos, F. Morais, I. Gottlieb, M. Hadlich, T. Rothstein, M. Tauil, N. Veras, M. Vaisman, F. Teixeira Pde, Subclinical hypothyroidism represents an additional risk factor for coronary artery calcification, especially in subjects with intermediate and high cardiovascular risk scores. Eur. J. Endocrinol. 171, 327–34 (2014). https://doi.org/10.1530/EJE-14-0031CrossRefPubMed

14.

F.L.J. Visseren, F. Mach, Y.M. Smulders, D. Carballo, K.C. Koskinas, M. Bäck, A. Benetos, A. Biffi, J.M. Boavida, D. Capodanno, B. Cosyns, C. Crawford, C.H. Davos, I. Desormais, E. Di Angelantonio, O.H. Franco, S. Halvorsen, F.D.R. Hobbs, M. Hollander, E.A. Jankowska, M. Michal, S. Sacco, N. Sattar, L. Tokgozoglu, S. Tonstad, K.P. Tsioufis, I. van Dis, I.C. van Gelder, C. Wanner, B. Williams; ESC National Cardiac Societies; ESC Scientific Document Group., 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227–3337 (2021). https://doi.org/10.1093/eurheartj/ehab484CrossRefPubMed

15.

Endocrine disorders and CVD. In: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine (2019).

16.

R. Mullur, Y.Y. Liu, G.A. Brent, Thyroid hormone regulation of metabolism. Physiol. Rev. 94, 355–382 (2014). https://doi.org/10.1152/physrev.00030.2013CrossRefPubMedPubMedCentral

17.

B. Gereben, A.M. Zavacki, S. Ribich, B.W. Kim, S.A. Huang, W.S. Simonides, A. Zeöld, A.C. Bianco, Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr. Rev. 29, 898–938 (2008). https://doi.org/10.1210/er.2008-0019CrossRefPubMedPubMedCentral

18.

I. Mourouzis, F. Forini, C. Pantos, G. Iervasi, Thyroid hormone and cardiac disease: from basic concepts to clinical application. J. Thyroid Res 2011, 958626 (2011). https://doi.org/10.4061/2011/958626CrossRefPubMedPubMedCentral

19.

J. Guirguis-Blake, C.M. Hales, Screening for thyroid disease. Am. Fam. Phys. 71, 1369–1370 (2005)

20.

S. Razvi, A. Jabbar, A. Pingitore, S. Danzi, B. Biondi, I. Klein, R. Peeters, A. Zaman, G. Iervasi, Thyroid Hormones and Cardiovascular Function and Diseases. J. Am. Coll. Cardiol. 71, 1781–1796 (2018). https://doi.org/10.1016/j.jacc.2018.02.045CrossRefPubMed

21.

A. Jabbar, A. Pingitore, S.H. Pearce, A. Zaman, G. Iervasi, S. Razvi, Thyroid hormones and CVD. Nat. Rev. Cardiol. 14, 39–55 (2017). https://doi.org/10.1038/nrcardio.2016.174CrossRefPubMed

22.

A.P. Delitala, G. Fanciulli, M. Maioli, G. Delitala, Subclinical hypothyroidism, lipid metabolism and CVD. Eur. J. Intern. Med. 38, 17–24 (2017). https://doi.org/10.1016/j.ejim.2016.12.015CrossRefPubMed

23.

B.D. Hoit, S.F. Khoury, Y. Shao, M. Gabel, S.B. Liggett, R.A. Walsh, Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation 96, 592–598 (1997). https://doi.org/10.1161/01.cir.96.2.592CrossRefPubMed

24.

T.M. Ortiga-Carvalho, M.I. Chiamolera, C.C. Pazos-Moura, F.E. Wondisford, Hypothalamus-Pituitary-Thyroid Axis. Compr. Physiol. 6, 1387–1428 (2016). https://doi.org/10.1002/cphy.c150027CrossRefPubMed

25.

L. Sabatino, G. Iervasi, A. Pingitore, Thyroid hormone and heart failure: from myocardial protection to systemic regulation. Expert Rev. Cardiovasc. Ther. 12, 1227–1236 (2014). https://doi.org/10.1586/14779072.2014.957674CrossRefPubMed

26.

P.M. Yen, Thyroid Hormones and 3,5-Diiodothyropropionic Acid: New Keys for New Locks. Endocrin 147, 1598–1601 (2006). https://doi.org/10.1210/en.2006-0074CrossRef

27.

G. Panagiotou, K. Pazaitou-Panayiotou, S.A. Paschou, D. Komninou, N. Kalogeris, A. Vryonidou, C.S. Mantzoros, Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans. Thyroid 26, 1039–1045 (2016). https://doi.org/10.1089/thy.2016.0098CrossRefPubMed

28.

R. Vicinanza, G. Coppotelli, C. Malacrino, T. Nardo, B. Buchetti, L. Lenti, F.S. Celi, S. Scarpa, Oxidized low-density lipoproteins impair endothelial function by inhibiting non-genomic action of thyroid hormone–mediated nitric oxide production in human endothelial cells. Thyroid 23, 231–238 (2013). https://doi.org/10.1089/thy.2011.0524CrossRefPubMedPubMedCentral

29.

G. Siasos, E. Bletsa, P.K. Stampouloglou, E. Oikonomou, V. Tsigkou, S.A. Paschou, K. Vlasis, G. Marinos, M. Vavuranakis, C. Stefanadis, D. Tousoulis, MicroRNAs in CVD. Hellenic J. Cardiol. 61165–173 (2020) https://doi.org/10.1016/j.hjc.2020.03.003

30.

D.S. Cooper, B. Biondi, Subclinical thyroid disease. Lancet 379, 1142–1154 (2012). https://doi.org/10.1016/S0140-6736(11)60276-6CrossRefPubMed

31.

I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501–509 (2001). https://doi.org/10.1056/NEJM200102153440707CrossRefPubMed

32.

K. Gauthier, F. Flamant, Nongenomic, TRβ-Dependent, Thyroid Hormone Response Gets Genetic Support. Endocrin 155, 3206–3209 (2014). https://doi.org/10.1210/en.2014-1597CrossRef

33.

A.L. deCastro, A.V. Tavares, C. Campos, R.O. Fernandes, R. Siqueira, A. Conzatti, A.M. Bicca, T.R. Fernandes, C.L. Sartório, P.C. Schenkel, A. Belló-Klein, A.S. da Rosa Araujo, Cardioprotective effects of thyroid hormones in a rat model of myocardial infarction are associated with oxidative stress reduction. Mol. Cell Biol. 391, 22–29 (2014). https://doi.org/10.1016/j.mce.2014.04.010CrossRef

34.

L. Kannan, P.A. Shaw, M.P. Morley, J. Brandimarto, J.C. Fang, N.K. Sweitzer, T.P. Cappola, A.R. Cappola, Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circ. Heart Fail 11, e005266 (2018). https://doi.org/10.1161/CIRCHEARTFAILURE.118.005266CrossRefPubMedPubMedCentral

35.

P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J.H. Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrino. 14, 301–316 (2018). https://doi.org/10.1038/nrendo.2018.18CrossRef

36.

J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 89–499 (2002). https://doi.org/10.1210/jcem.87.2.8182CrossRef

37.

B. Biondi, L. Bartalena, D.S. Cooper, L. Hegedüs, P. Laurberg, G.J. Kahaly, The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur. Thyroid J. 4, 149–163 (2015). https://doi.org/10.1159/000438750CrossRefPubMedPubMedCentral

38.

M.I. Surks, E. Ortiz, G.H. Daniels, C.T. Sawin, N.F. Col, R.H. Cobin, J.A. Franklyn, J.M. Hershman, K.D. Burman, M.A. Denke, C. Gorman, R.S. Cooper, N.J. Weissman, Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291, 228–238 (2004). https://doi.org/10.1001/jama.291.2.228CrossRefPubMed

39.

B. Biondi, G.J. Kahaly, Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat. Rev. Endocrinol. 6, 431–443 (2010). https://doi.org/10.1038/nrendo.2010.105CrossRefPubMed

40.

B. Li, Z. Li, Y. Huang, Investigating Changes in Cardiac Function and Structure of Left Ventricle by Speckle-Tracking Echocardiography in Patients With Hyperthyroidism and Graves’ Disease. Front. Cardiovasc. Med. 8, 695736 (2021). https://doi.org/10.3389/fcvm.2021.695736CrossRefPubMedPubMedCentral

41.

C.W. Siu, C.Y. Yeung, C.P. Lau, A.W. Kung, H.F. Tse, Incidence, clinical characteristics, and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93, 483–487 (2007). https://doi.org/10.1136/hrt.2006.100628CrossRefPubMed

42.

J.E. Mitchell, A.S. Hellkamp, D.B. Mark, J. Anderson, G.W. Johnson, J.E. Poole, K.L. Lee, G.H. Bardy, Thyroid function in heart failure and impact on mortality. JACC Heart Fail 1, 48–55 (2013). https://doi.org/10.1016/j.jchf.2012.10.004CrossRefPubMedPubMedCentral

43.

M. Rivas, J. Dennis, C. Pena, J. Kopel, K. Nugent, The association of hypertension and hyperthyroidism in a subspecialty clinic and a national data base. South Med. J. 113, 607–611 (2020). https://doi.org/10.14423/SMJ.0000000000001186CrossRefPubMed

44.

M. Lillevang-Johansen, B. Abrahamsen, H.L. Jørgensen, T.H. Brix, L. Hegedüs, Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. Thyroid 29, 332–340 (2019). https://doi.org/10.1089/thy.2018.0320CrossRefPubMed

45.

I.M. Grais, J.R. Sowers, Thyroid and the heart. Am. J. Med. 127, 691–698 (2014). https://doi.org/10.1016/j.amjmed.2014.03.009CrossRefPubMedPubMedCentral

46.

X. Song, K. Yang, G. Chen, W. Duan, D. Yao, S. Li, G. Yuan, L. Liu, Characteristics and Risk Factors of Pulmonary Hypertension in Patients With Hyperthyroidism. Endocr. Pr. 27, 918–924 (2021). https://doi.org/10.1016/j.eprac.2021.02.011CrossRef

47.

K. Riaz, A.D. Forker, W.L. Isley, M.S. Hamburg, P.A. McCullough, Hyperthyroidism: a „curable“ cause of congestive heart failure–three case reports and a review of the literature. Congest. Heart Fail 9, 40–46 (2013). https://doi.org/10.1111/j.1527-5299.2003.01124.xCrossRef

48.

V. Hernando, Role of Thyroid Hormones in Different Aspects of Cardiovascular System. Endocrinol. Metab. Synd. 4, 2 (2015)CrossRef

49.

G. Lerstad, K.F. Enga, R. Jorde, E.E. Brodin, J. Svartberg, S.K. Brækkan, J.B. Hansen, Thyroid function, as assessed by TSH, and future risk of venous thromboembolism: the Tromsø study. Eur. J. Endocrinol. 173, 83–90 (2015). https://doi.org/10.1530/EJE-15-0185CrossRefPubMed

50.

J. Debeij, B. van Zaane, O.M. Dekkers, C.J. Doggen, J.W. Smit, A.P. van Zanten, D.P. Brandjes, H.R. Büller, V.E. Gerdes, F.R. Rosendaal, S.C. Cannegieter, High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study. J. Thromb. Haemost. 12, 839–846 (2014). https://doi.org/10.1111/jth.12573CrossRefPubMed

51.

Atrial fibrillation and hyperthyroidism. In: The ESC Textbook of Cardiovascular Medicine 2018 (3rd edition).

52.

C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach, P.W. Wilson, E.J. Benjamin, R.B. D’Agostino, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994). https://doi.org/10.1056/NEJM199411103311901CrossRefPubMed

53.

P. Müller, J.W. Dietrich, T. Lin, A. Bejinariu, S. Binnebößel, F. Bergen, J. Schmidt, S.K. Müller, A. Chatzitomaris, M. Kurt, S. Gerguri, L. Clasen, H.H. Klein, M. Kelm, H. Makimoto, Usefulness of Serum Free Thyroxine Concentration to Predict Ventricular Arrhythmia Risk in Euthyroid Patients With Structural Heart Disease. Am. J. Cardiol. 125, 1162–1169 (2020). https://doi.org/10.1016/j.amjcard.2020.01.019CrossRefPubMed

54.

Z.H. Zhou, L.L. Ma, L.X. Wang, Risk Factors for Persistent Atrial Fibrillation Following Successful Hyperthyroidism Treatment with Radioiodine Therapy. Intern. Med. 50, 2947–2951 (2011). https://doi.org/10.2169/internalmedicine.50.6135CrossRefPubMed

55.

K. Kim, P.S. Yang, E. Jang, H.T. Yu, T.H. Kim, J.S. Uhm, J.Y. Kim, J.H. Sung, H.N. Pak, M.H. Lee, G.Y.H. Lip, B. Joung, Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: a nationwide cohort study. Am. Heart J. 242, 123–131 (2021). https://doi.org/10.1016/j.ahj.2021.08.018CrossRefPubMed

56.

S.B. Smedegaard, A.L. Riis, M.K. Christiansen, J.K.S. Linde, Subclinical hyperthyroidism and the risk of developing cardiovascular disease - a systematic review. Dan. Med. J. 67, A12190701 (2020)PubMed

57.

M.M. Martin, M.R. Collins, Nonischemic cardiomyopathy with reduced ejection fraction secondary to hyperthyroidism. JAAPA 34, 27–30 (2021). https://doi.org/10.1097/01.JAA.0000735812.69357.c5CrossRefPubMed

58.

J.A. Naser, S. Pislaru, M.N. Stan, G. Lin, Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves’ disease. Heart 6, heartjnl-2021-319752 (2021). https://doi.org/10.1136/heartjnl-2021-319752CrossRef

59.

E. Ryödi, S. Metso, H. Huhtala, M. Välimäki, A. Auvinen, P. Jaatinen, Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy. Thyroid 28, 1111–1120 (2018). https://doi.org/10.1089/thy.2017.0461CrossRefPubMed

60.

B. Biondi, D.S. Cooper, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20, 135–146 (2010). https://doi.org/10.1089/thy.2009.0311CrossRefPubMed

61.

P. Giesecke, V. Frykman, G. Wallin, S. Lönn, A. Discacciati, O. Törring, M. Rosenqvist, All-cause and cardiovascular mortality risk after surgery versus radioiodine treatment for hyperthyroidism. Br. J. Surg. 105, 279–286 (2018). https://doi.org/10.1002/bjs.10665CrossRefPubMed

62.

F. Bogazzi, L. Bartalena, E. Martino, Approach to the patient with amiodarone-induced thyrotoxicosis. J. Clin. Endocrinol. Metab. 95, 2529–2535 (2010). https://doi.org/10.1210/jc.2010-0180CrossRefPubMed

63.

D. Portelli, S. Mifsud, A. Abela, S. Fava, Amiodarone-induced type 2 thyrotoxicosis. BMJ Case Rep. 14, e238145 (2021). https://doi.org/10.1136/bcr-2020-238145CrossRefPubMed

64.

A. Theodoraki, M.P.J. Vanderpump, Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin. Endocrinol. (Oxf.) 84, 172–176 (2018). https://doi.org/10.1111/cen.12988CrossRef

65.

L. Bartalena, F. Bogazzi, L. Chiovato, A. Hubalewska-Dydejczyk, T.P. Links, M. Vanderpump, 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur. Thyroid J. 7, 55–66 (2018). https://doi.org/10.1159/000486957CrossRefPubMedPubMedCentral

66.

V. Calsolaro, G. Pasqualetti, A.M. Calabrese, A. Polini, C. Okoye, S. Magno, N. Caraccio, F. Monzani, Overt and subclinical hypothyroidism in the elderly: when to treat? Front. Endocrinol. 10, 177 (2019). https://doi.org/10.3389/fendo.2019.00177CrossRef

67.

S.H. Pearce, G. Brabant, L.H. Duntas, F. Monzani, R.P. Peeters, S. Razvi, J.L. Wemeau, 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2, 215–228 (2013). https://doi.org/10.1159/000356507CrossRefPubMedPubMedCentral

68.

J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults., American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pr. 18, 988–1028 (2012). https://doi.org/10.4158/EP12280.GLCrossRef

69.

A. Mancini, C. Di Segni, S. Raimondo, G. Olivieri, A. Silvestrini, E. Meucci, D. Currò, Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm. 2016, 6757154 (2016). https://doi.org/10.1155/2016/6757154CrossRefPubMedPubMedCentral

70.

R. Silva-Tinoco, L. Castillo-Martínez, A. Orea-Tejeda, J.J. Orozco-Gutiérrez, O. Vázquez-Díaz, P. Montaño-Hernández, A. Flores-Rebollar, A. Reza-Albarrán, Developing thyroid disorders is associated with poor prognosis factors in patient with stable chronic heart failure. Int J. Cardiol. 147, e24–e25 (2011). https://doi.org/10.1016/j.ijcard.2009.01.012CrossRefPubMed

71.

K.Y. Jung, H.Y. Ahn, S.K. Han, Y.J. Park, B.Y. Cho, M.K. Moon, Association between thyroid function and lipid profiles, apolipoproteins, and high density lipoprotein function. J. Clin. Lipido. 11, 1347–1353 (2017). https://doi.org/10.1016/j.jacl.2017.08.015CrossRef

72.

A. Squizzato, E. Romualdi, H.R. Buller, V.E.A. Gerdes, Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J. Clin. Endocrinol. Metab. 92, 2415–2420 (2007). https://doi.org/10.1210/jc.2007-0199CrossRefPubMed

73.

A.R. Cappola, P.W. Ladenson, Hypothyroidism and atherosclerosis. J. Clin. Endocrinol. Metab. 88, 2438–2444 (2003). https://doi.org/10.1210/jc.2003-030398CrossRefPubMed

74.

A.N. Kaftan, F.H. Naser, M.A. Enaya, Changes of Certain Metabolic and Cardiovascular Markers Fructosamine, H-FABP and Lipoprotein (a) in Patients with Hypothyroidism. Med. Arch. 75, 11–15 (2021). https://doi.org/10.5455/medarh.2021.75.11-15CrossRefPubMedPubMedCentral

75.

N.A. van Vliet, M.M. Bos, C.S. Thesing, L. Chaker, M. Pietzner, E. Houtman, M.J. Neville, R. Li-Gao, S. Trompet, R. Mustafa, F. Ahmadizar, M. Beekman, M. Bot, K. Budde, C. Christodoulides, A. Dehghan, C. Delles, P. Elliott, M. Evangelou, H. Gao, M. Ghanbari, A.E. van Herwaarden, M.A. Ikram, M. Jaeger, J.W. Jukema, I. Karaman, F. Karpe, M. Kloppenburg, J.M.T.A. Meessen, I. Meulenbelt, Y. Milaneschi, S.P. Mooijaart, D.O. Mook-Kanamori, M.G. Netea, R.T. Netea-Maier, R.P. Peeters, B.W.J.H. Penninx, N. Sattar, P.E. Slagboom, H.E.D. Suchiman, H. Völzke, K. Willems van Dijk, R. Noordam, D. van Heemst; BBMRI Metabolomics Consortium., Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling. BMC Med. 19, 266 (2021). https://doi.org/10.1186/s12916-021-02130-1CrossRefPubMedPubMedCentral

76.

M. Khazan, A. Amouzegar, S. Gharibzadeh, L. Mehran, M. Tohidi, F. Azizi, Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS). Horm. Metab. Res. 46, 980–984 (2014). https://doi.org/10.1055/s-0034-1389997CrossRefPubMed

77.

X.L. Liu, S. He, S.F. Zhang, J. Wang, X.F. Sun, C.M. Gong, S.J. Zheng, J.C. Zhou, J. Xu, Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Med Sci. Monit. 20, 1432–1441 (2014). https://doi.org/10.12659/MSM.891163CrossRefPubMedPubMedCentral

78.

S.A. Paschou, G. Siasos, E. Bletsa, P.K. Stampouloglou, E. Oikonomou, A.S. Antonopoulos, K. Batzias, V. Tsigkou, K. Mourouzis, A. Vryonidou, N. Tentolouris, M. Vavouranakis, D. Tousoulis, The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: a Systematic Review of Randomized Placebo-controlled Trials. Curr. Pharm. Des. 26, 5980–5987 (2020). https://doi.org/10.2174/1381612826666200417153241CrossRefPubMed

79.

M. Spartalis, E. Spartalis, A. Athanasiou, S.A. Paschou, C. Kontogiannis, G. Georgiopoulos, D.C. Iliopoulos, V. Voudris, The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms. Curr. Med. Chem. 27, 1041–1051 (2020). https://doi.org/10.2174/0929867326666190911141951CrossRefPubMed

80.

N. Gong, C. Gao, X. Chen, Y. Fang, L. Tian, Endothelial Function in Patients with Subclinical Hypothyroidism: a Meta-Analysis. Horm. Metab. Res. 51, 691–702 (2019). https://doi.org/10.1055/a-1018-9564CrossRefPubMed

81.

P. Cai, Y. Peng, Y. Chen, Y. Wang, X. Wang, Blood pressure characteristics of subclinical hypothyroidism: an observation study combined with office blood pressure and 24-h ambulatory blood pressure. J. Hypertens. 39, 453–460 (2021). https://doi.org/10.1097/HJH.0000000000002655CrossRefPubMed

82.

M.S. Saric, M.J. Jurasic, H. Budincevic, M. Milosevic, B. Kranjcec, S. Kovacic, J. Leskovar, V. Demarin, The role of thyroid hormones in carotid arterial wall remodeling in women. Rom. J. Intern. Med. (2021) https://doi.org/10.2478/rjim-2021-0028

83.

E. Asoğlu, T. Akbulut, Z. Doğan, R. Asoğlu, Evaluation of the aortic velocity propagation, epicardial fat thickness, and carotid intima-media thickness in patients with subclinical hypothyroidism. Rev. Cardiovasc. Med. 22, 959–966 (2021). https://doi.org/10.31083/j.rcm2203104CrossRefPubMed

84.

J. Kim, N. Prasitlumkum, S. Randhawa, D. Banerjee, Association between Subclinical Hypothyroidism and Incident Hypertension in Women: A Systematic Review and Meta-Analysis. J. Clin. Med. 10, 3318 (2021). https://doi.org/10.3390/jcm10153318CrossRefPubMedPubMedCentral

85.

M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 85, 2993–3001 (2000). https://doi.org/10.1210/jcem.85.9.6841CrossRefPubMed

86.

K. Nakanishi, M. Daimon, Y. Yoshida, N. Sawada, K. Hirose, K. Iwama, Y. Yamamoto, J. Ishiwata, M. Hirokawa, H. Kaneko, T. Nakao, Y. Mizuno, H. Morita, M.R. Di Tullio, S. Homma, I. Komuro, Subclinical Hypothyroidism as an Independent Determinant of Left Atrial Dysfunction in the General Population. J. Clin. Endocrinol. Metab. 106, e1859–e1867 (2021). https://doi.org/10.1210/clinem/dgaa730CrossRefPubMed

87.

S. Alamdari, A. Amouzegar, M. Tohidi, S. Gharibzadeh, P. Kheirkhah, P. Kheirkhah, F. Azizi, Hypothyroidism and Lipid Levels in a Community Based Study (TTS). Int J. Endocrinol. Metab. 14, e22827 (2015). https://doi.org/10.5812/ijem.22827CrossRefPubMedPubMedCentral

88.

G. Yang, Y.A. Wang, A. Ma, T. Wang, Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. BMC Cardiovasc. Disord. 19, 83 (2019). https://doi.org/10.1186/s12872-019-1055-xCrossRefPubMedPubMedCentral

89.

X.Z. Zhou, R. Shi, J. Wang, K. Shi, X. Liu, Y. Li, Y. Gao, Y.K. Guo, Z.G. Yang, Characteristics of coronary artery disease in patients with subclinical hypothyroidism: evaluation using coronary artery computed tomography angiography. BMC Cardiovasc. Disord. 21, 303 (2021). https://doi.org/10.1186/s12872-021-02116-0CrossRefPubMedPubMedCentral

90.

K. Inoue, B. Ritz, G.A. Brent, R. Ebrahimi, C.M. Rhee, A.M. Leung, Association of Subclinical Hypothyroidism and Cardiovascular Disease With Mortality. JAMA Netw. Open 3, e1920745 (2020). https://doi.org/10.1001/jamanetworkopen.2019.20745CrossRefPubMed

91.

S. Ozturk, A. Alcelik, M. Ozyasar, O. Dikbas, S. Ayhan, F. Ozlu, A. Erdem, M. Tosun, D. Baltaci, M. Yazici, Evaluation of left ventricular systolic asynchrony in patients with subclinical hypothyroidism. Cardiol. J. 19, 374–380 (2012). https://doi.org/10.5603/cj.2012.0068CrossRefPubMed

92.

S. Ilic, M. Tadic, B. Ivanovic, Z. Caparevic, B. Trbojevic, V. Celic, Left and right ventricular structure and function in subclinical hypothyroidism: the effects of one-year levothyroxine treatment. Med. Sci. Monit. 19, 960–968 (2013). https://doi.org/10.12659/MSM.889621CrossRefPubMedPubMedCentral

93.

A. AlQahtani, Z. Alakkas, F. Althobaiti, M. Alosaimi, B. Abuzinadah, E. Abdulkhalik, K. Alswat, Thyroid Dysfunction in Patients Admitted in Cardiac Care Unit: Prevalence, Characteristic and Hospitalization Outcomes. Int J. Gen. Med. 14, 505–514 (2021). https://doi.org/10.2147/IJGM.S292750CrossRefPubMedPubMedCentral

94.

A. Jabbar, L. Ingoe, H. Thomas, P. Carey, S. Junejo, C. Addison, J. Vernazza, D. Austin, J.P. Greenwood, A. Zaman, S. Razvi, Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J. Endocrinol. Investig. 44, 1209–1218 (2021). https://doi.org/10.1007/s40618-020-01408-0CrossRef

95.

M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr, M.M. Colvin, M.H. Drazner, G.S. Filippatos, G.C. Fonarow, M.M. Givertz, S.M. Hollenberg, J. Lindenfeld, F.A. Masoudi, P.E. McBride, P.N. Peterson, L.W. Stevenson, C. Westlake, 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 70, 776–803 (2017). https://doi.org/10.1016/j.jacc.2017.04.025CrossRefPubMed

96.

T.A. McDonagh, M. Metra, M. Adamo, R.S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, J.G.F. Cleland, A.J.S. Coats, M.G. Crespo-Leiro, D. Farmakis, M. Gilard, S. Heymans, A.W. Hoes, T. Jaarsma, E.A. Jankowska, M. Lainscak, C.S.P. Lam, A.R. Lyon, J.J.V. McMurray, A. Mebazaa, R. Mindham, C. Muneretto, M. Francesco Piepoli, S. Price, G.M.C. Rosano, F. Ruschitzka, A. Kathrine Skibelund; ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021). https://doi.org/10.1093/eurheartj/ehab368CrossRefPubMed

97.

G. Pasqualetti, S. Tognini, A. Polini, N. Caraccio, F. Monzani, Subclinical hypothyroidism and heart failure risk in older people. Endocr. Metab. Immune Disord. Drug Targets 13, 13–21 (2013). https://doi.org/10.2174/1871530311313010004CrossRefPubMed

98.

M.N. Andersen, A.M. Olsen, J.C. Madsen, J. Faber, C. Torp-Pedersen, G.H. Gislason, C. Selmer, Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality. PLoS ONE 10, e0129793 (2015). https://doi.org/10.1371/journal.pone.0129793CrossRefPubMedPubMedCentral

99.

A. Jabbar, L. Ingoe, S. Junejo, P. Carey, C. Addison, H. Thomas, J.D. Parikh, D. Austin, K.G. Hollingsworth, D.D. Stocken, S.H.S. Pearce, J.P. Greenwood, A. Zaman, S. Razvi, Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA 324, 249–258 (2020). https://doi.org/10.1001/jama.2020.9389CrossRefPubMed

100.

D.J. Stott, N. Rodondi, P.M. Kearney, I. Ford, R.G.J. Westendorp, S.P. Mooijaart, N. Sattar, C.E. Aubert, D. Aujesky, D.C. Bauer, C. Baumgartner, M.R. Blum, J.P. Browne, S. Byrne, T.H. Collet, O.M. Dekkers, W.P.J. den Elzen, R.S. Du Puy, G. Ellis, M. Feller, C. Floriani, K. Hendry, C. Hurley, J.W. Jukema, S. Kean, M. Kelly, D. Krebs, P. Langhorne, G. McCarthy, V. McCarthy, A. McConnachie, M. McDade, M. Messow, A. O’Flynn, D. O’Riordan, R.K.E. Poortvliet, T.J. Quinn, A. Russell, C. Sinnott, J.W.A. Smit, H.A. Van Dorland, K.A. Walsh, E.K. Walsh, T. Watt, R. Wilson, J. Gussekloo, TRUST Study Group.: thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 376, 2534–2544 (2017). https://doi.org/10.1056/NEJMoa1603825CrossRefPubMed

101.

L.E. Zijlstra, J.W. Jukema, R.G.J. Westendorp, R.S. Du Puy, R.K.E. Poortvliet, P.M. Kearney, L. O’Keeffe, O.M. Dekkers, M.R. Blum, N. Rodondi, T.H. Collet, T.J. Quinn, N. Sattar, D.J. Stott, S. Trompet, W.P.J. den Elzen, J. Gussekloo, S.P. Mooijaart, Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials. Front. Endocrinol. (Lausanne) 12, 674841 (2021). https://doi.org/10.3389/fendo.2021.674841CrossRef

102.

C.C. Peng, H.K. Huang, B.B. Wu, R.H. Chang, Y.K. Tu, K.M. Munir, Association of Thyroid Hormone Therapy with Mortality in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 106, 292–303 (2021). https://doi.org/10.1210/clinem/dgaa777CrossRefPubMed

103.

J.V. Hennessey, R. Espaillat, Diagnosis and management of subclinical hypothyroidism in elderly adults: a review of the literature. J. Am. Geriatr. Soc. 63, 1663–1673 (2015). https://doi.org/10.1111/jgs.13532CrossRefPubMed

104.

N. Niknam, N. Khalili, E. Khosravi, M. Nourbakhsh, Endothelial dysfunction in patients with subclinical hypothyroidism and effects of treatment with levothyroxine. Adv. Biomed. Res. 5, 38 (2016). https://doi.org/10.4103/2277-9175.178783CrossRefPubMedPubMedCentral

105.

E. Oikonomou, G. Siasos, V. Tsigkou, E. Bletsa, M.E. Panoilia, I.N. Oikonomou, I. Simanidis, M. Spinou, A. Papastavrou, G. Kokosias, M. Zaromitidou, P. Stampouloglou, M. Spartalis, M. Vavuranakis, C. Stefanadis, A.G. Papavassiliou, D. Tousoulis, Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches. Curr. Med. Chem. 27, 1052–1080 (2020). https://doi.org/10.2174/0929867326666190830103219CrossRefPubMed

106.

I.M. Abreu, E. Lau, B. de Sousa Pint, D. Carvalho, Subclinical hypothyroidism: to treat or not to treat, that is the question!. A systematic review with meta-analysis on lipid profile. Endocr. Connect. 6,188–199 (2017) https://doi.org/10.1530/EC-17-0028

107.

M. Aziz, Y. Kandimalla, A. Machavarapu, A. Saxena, S. Das, A. Younus, M. Nguyen, R. Malik, D. Anugula, M.A. Latif, C. Humayun, I.M. Khan, A. Adus, A. Rasool, E. Veledar, K. Nasir, Effect of Thyroxin Treatment on Carotid Intima-Media Thickness (CIMT) Reduction in Patients with Subclinical Hypothyroidism (SCH): a Meta-Analysis of Clinical Trials. J. Atheroscler. Thromb. 24, 643–659 (2017). https://doi.org/10.5551/jat.39917CrossRefPubMedPubMedCentral

Titel: Thyroid disorders and cardiovascular manifestations: an update
verfasst von: Stavroula A. Paschou
Evanthia Bletsa
Panagiota K. Stampouloglou
Vasiliki Tsigkou
Angeliki Valatsou
Katerina Stefanaki
Paraskevi Kazakou
Michael Spartalis
Eleftherios Spartalis
Evangelos Oikonomou
Gerasimos Siasos
Publikationsdatum: 15.01.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-02982-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Operation bei Blasenkrebs/© anistidesign / Fotolia, Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Mann wird von Ärztin untersucht/© Tashi-Delek, Getty Images, iStock (Symbolbild mit Fotomodellen)

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Irisin: circulating levels in serum and its relation to gonadal axis

Association of decreased muscle mass with reduced bone mineral density in patients with Graves’ disease

Can ultrasensitive thyroglobulin immunoassays avoid the need for ultrasound in thyroid cancer follow-up?

Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study

Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma